Substance / Medication

Colestipol hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

20 trials linked to this intervention

20
Total Trials
0
Recruiting
10
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Apolipoprotein C-III inhibitors for the treatment of hypertriglyceridemia: a meta-analysis of randomized controlled trials.
de Moura de Souza Mariana, Mendes Beatriz Ximenes, Defante Maria Luiza Rodrigues et al. · Metabolism · 2025
PMID: 40074058Meta-Analysis
Global burden and characterization of hypertriglyceridemia-induced acute pancreatitis: results from a systematic review and a multi-center cohort study.
Fan Zhengyang, Zhang Yuelun, Li Jianing et al. · Sci China Life Sci · 2025
PMID: 40550999Meta-Analysis
Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis.
Ballena-Caicedo Jhosmer, Zuzunaga-Montoya Fiorella E, Loayza-Castro Joan A et al. · J Health Popul Nutr · 2025
PMID: 40859400Meta-AnalysisFull text (PMC)
Hypertriglyceridemia is a dose-dependent risk factor for type 2 diabetes mellitus: a systematic review and meta-analysis.
Havelda Luca, Szalai Eszter Ágnes, Obeidat Mahmoud et al. · Front Endocrinol (Lausanne) · 2025
PMID: 41268155Meta-AnalysisFull text (PMC)
Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis.
Masson Walter, Lobo Martín, Nogueira Juan P et al. · Rev Endocr Metab Disord · 2024
PMID: 38997541Meta-Analysis
Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.
Robertson Derrick, Dixon Crystal, Aungst Angela et al. · Expert Rev Clin Pharmacol · 2017
PMID: 29064296Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Colestipol hydrochloride (substance)
SNOMED CT
55316001
UMLS CUI
C0354648

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
20
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.